Blood and tumor markers to test response to abemaciclib
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies how the immune system and other body signals in blood and tumor tissue relate to how well abemaciclib works before breast cancer surgery. The goal is to learn who benefits most from this medicine and why.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage breast cancer (stage I, II, or III) that is estrogen- or progesterone-receptor positive and HER2 negative.
- You are post-menopausal (for example, age 55+, or at least 12 months with no periods, or specific blood test hormone levels).
- Your breast tumor is at least 1 cm and your team can take tissue samples before and after treatment.
- You must be able to take and swallow the study pills by mouth, and you can sign consent.
- Your recent blood tests and organ function look safe enough for treatment (including blood counts, liver/kidney tests, and creatinine clearance >30).
- You plan a short course of hormone-based treatment before other cancer treatment or surgery (typically about 2 weeks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a targeted therapy (abemaciclib) to standard chemotherapy before surgery can shrink tumors and improve outcomes in hormone-positive, HER2-negative early breast cancer. It also uses a genetic test (Oncotype DX) to help guide surgical choices.
This trial combines a short course of radiation before surgery with two oral medications (abemaciclib and letrozole) to treat early-stage, hormone-sensitive breast cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether a targeted therapy (abemaciclib) combined with focused radiation (SBRT) to a bone tumor can help people with advanced breast cancer. It is for patients whose cancer is hormone receptor positive and HER2 negative, and who will continue abemaciclib after radiation.
This trial tests a drug called abemaciclib for people with early-stage, hormone-receptor-positive, HER2-negative breast cancer who still have cancer DNA in their blood after completing standard treatment. It aims to see if taking this drug can reduce the chance of cancer coming back.
This Phase 1/2 trial tests whether combining abemaciclib with bicalutamide can slow or shrink HER2-negative, androgen receptor–positive (AR-positive) metastatic breast cancer. It mainly looks at safety and side effects, and also whether the combination can help patients with this type of breast cancer.
This study looks at how the body handles the drug abemaciclib, and how it relates to severe diarrhea, which is a common side effect. It is for people with high-risk, hormone receptor positive breast cancer who have already had surgery. The goal is to better understand and possibly manage diarrhea, so you can stay on treatment.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.